by OTMS Staff | Jun 2, 2026 | PatentVest Pulse
PatentVest Pulse — The Muscle ProblemPATENTVEST PULSEThe Muscle Problem: How Myostatin Could Expand the GLP-1 OpportunityBeyond GLP-1 Series, Report #5 of 12 | June 2026When a patient loses 50 pounds on a GLP-1, somewhere between 12 and 20 of those pounds is lean body...
by OTMS Staff | Apr 23, 2026 | PatentVest Pulse, Uncategorized
PatentVest Pulse — The Triple-Agonist RacePatentVest PulseThe Triple-Agonist RaceRetatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market.April 2026Ozempic and Wegovy built a $50B market with 15% weight loss. Mounjaro and Zepbound...
by OTMS Staff | Mar 27, 2026 | Legal Reports
PatentVest Pulse Using AI In Your Inventive Process? Proceed to Patent, But Carefully Article | March 2026 The U.S. Patent and Trademark Office has sent a clear message to innovators: inventions involving AI may be patentable, including in biotech and healthcare, but...
by OTMS Staff | Mar 25, 2026 | PatentVest Pulse
PatentVest Pulse — The Amylin RenaissancePATENTVEST PULSEThe Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity MedicineReport #2 | March 2026GLP-1 receptor agonists built a $71 billion market by making patients...
by OTMS Staff | Feb 25, 2026 | PatentVest Pulse
Author: Tyler Teske Wegovy and Zepbound (semaglutide, tirzepatide) built a $71 billion market by treating less than 5% of eligible patients. The other 95% remain untreated, not because the drugs don’t work, but because needles, cold chains, and $1,000-per-month...
Recent Comments